VIR: Vir Biotechnology Inc Price to Earnings Ratio

Symbol and logo of brand Vir Bio (VIR)

Vir Biotechnology, Inc. (VIR) is currently revising its development vector, shifting its focus toward hepatitis and oncology. Strict FDA oversight and a robust patent portfolio provide business protection, while delivery relies on a sophisticated cooling system. The company's P/E ratio clearly demonstrates the valuation dynamics relative to earnings, where -9.00 reflects the most recent value of the metric.

vir.bio (VIR) Price to Earnings Ratio: for the period 07/04/2022 - 11/14/2026

Analytical breakdowns for Vir Biotechnology, Inc.

- share price and expert price forecast:
Price Performance Chart vir.bio|VIR - Consensus Target
- market capitalization information:
Market Value Vir Biotechnology, Inc.|VIR - Enterprise Value
- book capitalization information:
Net Assets per Share Vir Biotechnology|VIR - Company Book Value|Market Value to Book Value vir.bio|VIR - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Vir Biotechnology, Inc.|VIR - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Vir Corp|VIR - Company Total Debt|Debt to Book Capitalization Ratio Vir Biotechnology, Inc.|VIR - Company Long-Term Debts|Short-Term Debt Volume Vir Biotechnology|Intermediate Coverage Ratio vir.bio
- earnings and market multiples details:
VIR - Net Income|Expected Net Income Vir Biotechnology, Inc.|VIR - P/E Multiple|Future Price to Earnings Vir Biotechnology Inc|VIR - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Vir Biotechnology, Inc.|VIR - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Vir Biotechnology|VIR - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months vir.bio|VIR - Earnings growth in current year|Expected net earnings per share growth next year Vir Biotechnology, Inc.
- sales volume and revenue indicators:
VIR - Revenue and Sales Volume|Company Future Sales Volume vir.bio|VIR - P/S Multiple|Forward Price to Sales Vir Biotechnology, Inc.
General company analysis:vir.bio
Core merchandise of Vir Biotechnology, Inc.

Vir Biotechnology, Inc. (VIR) is driving its market valuation dynamics via the P/E ratio, as the development of innovative antibodies to combat hepatitis B/D reflects investor expectations for the clinical success of tobevibart. This ratio, calculated as market capitalization divided by net income, measures the investment payback period, allowing for a comparison between the business value and its actual ability to generate income against a backdrop of significant cash reserves.

Key competitors

GILD: Company Value to Net Income|Price to Earnings Ratio CDTX (Cidara Corp)|Price to Earnings Ratio NVAX (Novavax Inc)|P/E Multiple CVAC (CureVac Corp)|Business Payback Period Valneva Vaccines (VALN)|SIGA - Price to Earnings Ratio|Company Value to Net Income EBS (emergentbiosolutions.com)|AVIR (Atea Pharmaceuticals, Inc.) - Price to Earnings Ratio|Invivyd (IVVD) - P/E Multiple|Price to Earnings Ratio Enanta|Inovio Pharma (INO) - Business Payback Period|Price to Earnings Ratio HLVX (HilleVax, Inc.)|Price to Earnings Ratio KLRS (kalaristx.com)|P/E Multiple DYAI (Dyadic International, Inc.)|Business Payback Period NanoViricides Inc. (NNVC)|TLPH - Price to Earnings Ratio|Company Value to Net Income COCP (Cocrystal Pharma Corp)|TRAW (trawspharma.com) - Price to Earnings Ratio|Dogwood Therapeutics - Company Value to Net Income|QLGN (Qualigen Therapeutics, Inc.) - P/E Multiple|Price to Earnings Ratio ALVR|P/E Multiple VBIV|Business Payback Period virios.com|Price to Earnings Ratio Vaxart VXRT